Cut through the noise.
Trade on the signal.

Evidence Reveals Pulse Biosciences Is A Joke – It’s Years Late To The Pulsed Field Ablation Market And Its “Nanosecond” Technology Is Impractical And Not Novel – $1 Price Target

Pulse Biosciences (PLSE) faces critical challenges in cardiac ablation technology, burning $15M quarterly with minimal revenue, unproven nsPFA technology, and significant bankruptcy risks in competitive medical device...